市场调查报告书
商品编码
1464799
管腔成形术市场:依手术技术、应用划分 - 2024-2030 年全球预测Canaloplasty Market by Surgical Technique (Ab-Externo Canaloplasty, Ab-Interno Canaloplasty), Application (Academy & Research Laboratory, Ambulatory Surgical Centers, Hospitals & Ophthalmology Clinics) - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
管腔成形术市场规模预计2023年为5.1726亿美元,2024年达到5.5404亿美元,预计2030年将达到8.4515亿美元,复合年增长率为7.26%。
泪管成形术是一种用于治疗青光眼的医疗手术。青光眼是一种由眼内压升高引起的慢性眼部疾病,导致视神经损伤并最终丧失视力。与更具侵入性的手术方法不同,眼管成形术使用微导管来拓宽眼睛的自然引流通道,使房水(有助于维持眼内压的液体)的流出更容易进行。这种方法是传统手术的一种较不侵入性的替代方法,旨在降低眼内压,同时最大限度地减少与侵入性手术相关的风险。由于全球青光眼盛行率不断上升以及对微创手术解决方案的需求不断增长,管道成形术市场正在经历显着增长。人口老化、对青光眼的认识不断提高以及医疗技术的进步正在进一步推动市场向前发展。然而,市场面临着手术成本高昂以及患者和医生更容易获得的替代治疗方法(例如药物和其他外科手术)的可用性等挑战。旨在提高微创手术疗效和安全性的研究和开发正在进行中,加上医疗保健基础设施的增长和患者对微创手术的偏好不断增加,为预期的市场扩张提供了肥沃的土壤。此外,提高血管成形术的可负担性和可及性的努力可能会为青光眼治疗领域的相关人员带来光明的前景,并增加其采用率。
主要市场统计 | |
---|---|
基准年[2023] | 51726万美元 |
预测年份 [2024] | 55404万美元 |
预测年份 [2030] | 8.4515亿美元 |
复合年增长率(%) | 7.26% |
手术技术:Abextanol 腔成形术技术因其微创性质而越来越受欢迎
Abextanocanaloplasty 是一种手术,外科医生在眼部组织上做一个小切口以进入施累姆管,施累姆管是眼睛引流系统的重要组成部分。一旦进入,将微导管插入管中以促进液体排放。外科医生还可以注射凝胶状物质以保持管子打开。这种方法作为一种比传统青光眼手术侵入性较小的选择而受到关注,因为它可以在不完全切除眼组织的情况下显着降低眼内压。相比之下,眼球内腔成形术是在眼球内部进行的。这是一种利用角膜上的微小切口直接进入施累姆氏管的新方法。与 abextano 手术类似,使用微导管和特殊器械来扩张管腔并允许液体排放,但不进行外部切口。这种方法通常是首选,因为它侵入性较小,恢復时间较快,并且可以与其他微创青光眼手术 (MIGS) 结合使用,以提供更好的压力控制。
应用:管腔成形术在医院和眼科诊所的新应用
在学术团体和研究机构中,管道成形术是一个研究主题,而不是直接应用于患者的治疗方法。当务之急是研究泪管成形术治疗青光眼的有效性、安全性和改善潜力。研究实验室和学术机构经常进行临床试验,分析结果,并将泪管成形术与其他青光眼治疗方法进行比较。这些环境旨在加深理解、完善技术并为有关这种微创手术的知识做出贡献。门诊手术中心 (ASC) 提供了一个患者无需住院即可接受手术的环境。使用 ASC 进行管道成形术强调了此手术的微创性,强调患者的便利性、成本节约和效率。医院和眼科诊所是接受管道成形术患者的主要治疗中心。这些设施拥有必要的基础设施和专业人员来执行这种精细的眼科手术。眼科诊所通常是大型医院系统的一部分或附属机构,并且拥有眼科护理方面的专业知识,包括我们提供擅长管道成形术的眼科医生。
区域洞察
在美洲,对眼管成形术的需求主要是由更容易患青光眼的老龄化人口以及有利于获得先进眼科护理的成熟医疗基础设施所推动的。该地区拥有活跃的法规环境,美国食品药物管理局(FDA) 等监管机构制定了严格的指导方针,以确保管道成形术设备和手术的安全性和有效性。在亚太地区 (APAC),经济的快速成长、医疗保健标准的提高以及医疗成本的上升正在刺激包括管道成形术在内的先进医疗方法的普及。该地区庞大的患者群体和人们对青光眼治疗选择的认识不断提高,导致对这种治疗方法的需求不断增长。欧洲、中东和非洲地区的管道成形术呈现出多样化的格局,在欧洲药品管理局 (EMA) 等强大监管机构的支持下,该技术的采用不断增加。这些组织确保管腔成形术设备符合高安全性和性能标准。同时,由于医疗基础设施投资增加以及对先进青光眼管理解决方案需求的日益认识,中东和非洲正在经历逐步成长。儘管存在这些不同的趋势,但在不断发展的监管标准和日益重视以患者为中心的护理的推动下,欧洲、中东和非洲地区的总体趋势包括我们正在逐渐接受微创手术。
FPNV定位矩阵
FPNV定位矩阵对于评估管道成形术市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对管腔成形术市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.管腔成形术市场的市场规模与预测是多少?
2.在Luminoplasty市场预测期间内需要考虑投资的产品、细分市场、应用和领域有哪些?
3.管腔成形术市场的技术趋势和法规结构是什么?
4.Luminoplasty市场主要供应商的市场占有率是多少?
5.进入管道成形术市场的合适型态和策略手段是什么?
[191 Pages Report] The Canaloplasty Market size was estimated at USD 517.26 million in 2023 and expected to reach USD 554.04 million in 2024, at a CAGR 7.26% to reach USD 845.15 million by 2030.
Canaloplasty is a medical procedure employed in treating glaucoma, a chronic condition of the eye due to increased intraocular pressure that can lead to optic nerve damage and, ultimately, loss of vision. Unlike more invasive surgical options, canaloplasty utilizes a microcatheter to enlarge the eye's natural drainage canal, facilitating a more manageable outflow of aqueous humor, the fluid responsible for maintaining eye pressure. This method presents a less aggressive alternative to traditional surgeries, aiming to reduce intraocular pressure while minimizing the risks associated with more invasive interventions. The canaloplasty market has witnessed significant growth, driven by the rising prevalence of glaucoma worldwide and the increasing need for less invasive surgical solutions. Aging populations, heightened awareness of glaucoma, and advancements in medical technology have further propelled the market forward. However, the market faces challenges, including the high cost of the procedure and the availability of alternative treatment options, including medication or other surgical procedures that may be more familiar to patients and practitioners. Furthermore, ongoing research and development aimed at enhancing the efficacy and safety of the method, coupled with growing healthcare infrastructure and increasing patient selection for minimally invasive surgeries, are expected to offer fertile ground for market expansion. Moreover, efforts to enhance the affordability and accessibility of canaloplasty can potentially increase its adoption, presenting a promising outlook for stakeholders in the glaucoma treatment landscape.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 517.26 million |
Estimated Year [2024] | USD 554.04 million |
Forecast Year [2030] | USD 845.15 million |
CAGR (%) | 7.26% |
Surgical Technique: Growing preference for the ab-interno canaloplasty technique for its minimally invasive nature
Ab-externo canaloplasty is where the surgeon creates a small incision in the eye tissue to access the schlemm's canal, a crucial component of the eye's drainage system. Once accessed, a microcatheter is inserted into the canal to enlarge and facilitate better fluid drainage. The surgeon may also inject a gel-like material to keep the canal open. This method is notable for significantly reducing intraocular pressure without requiring a complete removal of eye tissue, offering a less invasive option than traditional glaucoma surgeries. The ab-interno canaloplasty technique, in contrast, is performed from inside the eye. It is a newer approach involving a microscopic incision through the cornea to directly access the schlemm's canal. Similar to the ab-externo method, a microcatheter or a specialized device is used to dilate the canal and facilitate fluid drainage, whereas it is done without creating an external incision. This procedure is often preferred for its minimally invasive nature, reduced recovery times, and because it can be performed with other minimally invasive glaucoma surgeries (MIGS) to achieve better pressure control.
Application: Emerging applications of canaloplasty in hospitals and ophthalmology clinics
In academic and research laboratories, canaloplasty is a subject of study rather than a treatment applied directly to patients. These settings prioritize investigating the efficacy, safety, and potential improvements of canaloplasty as a treatment for glaucoma. Research labs and academic institutions often conduct clinical trials, analyze outcomes, and compare canaloplasty to other glaucoma treatments. These environments aim to advance understanding, refine techniques, and contribute to the knowledge surrounding this minimally invasive procedure. Ambulatory surgical centers (ASCs) offer a setting where patients can undergo this procedure without needing hospital admission. Using ASCs for canaloplasty underscores the procedure's minimally invasive nature, emphasizing patient convenience, reduced costs, and efficiency. Hospitals and ophthalmology clinics serve as primary points of care for patients undergoing canaloplasty. These institutions have the necessary infrastructure and specialized personnel to perform this delicate eye surgery. Ophthalmology clinics, often part of or affiliated with larger hospital systems, provide focused expertise in eye health, including access to ophthalmologists skilled in canaloplasty.
Regional Insights
In the Americas, the need for canaloplasty procedures is chiefly driven by an aging population vulnerable to glaucoma and an established healthcare infrastructure that facilitates access to advanced ophthalmic treatments. The region benefits from a proactive regulatory environment, with agencies, including the U.S. Food and Drug Administration (FDA), setting stringent guidelines that ensure the safety and efficacy of canaloplasty devices and procedures. In the Asia-Pacific (APAC) region, rapid economic growth, improved healthcare standards, and increased healthcare spending have catalyzed the adoption of advanced medical treatments, including canaloplasty. The region's vast patient pool and growing awareness about glaucoma management options contribute to the procedure's growing need. The EMEA region presents a diverse landscape for canaloplasty, with increasing technology adoption underpinned by strong regulatory bodies inlcuding the European Medicines Agency (EMA). These agencies ensure that canaloplasty devices meet high safety and performance standards. In contrast, the Middle East and Africa are gradually growing, driven by increasing investments in healthcare infrastructure and a growing recognition of the need for advanced glaucoma management solutions. Despite the diversity, the overarching trend in EMEA is towards embracing minimally invasive procedures like canaloplasty, facilitated by evolving regulatory standards and an increasing emphasis on patient-centered care.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Canaloplasty Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Canaloplasty Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Canaloplasty Market, highlighting leading vendors and their innovative profiles. These include Carl Zeiss Meditec AG, Ellex Medical Pty Ltd., Glaukos Corporation, iSTAR Medical, Nova Eye Medical Limited, Qura, Inc., and Sight Sciences, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Canaloplasty Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Canaloplasty Market?
3. What are the technology trends and regulatory frameworks in the Canaloplasty Market?
4. What is the market share of the leading vendors in the Canaloplasty Market?
5. Which modes and strategic moves are suitable for entering the Canaloplasty Market?